The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Acceleron Pharma Q3 EPS $(1.16) Down From $(0.66) YoY, Sales $34.20M Up From $22.56M YoY
Acceleron Pharma (NASDAQ:XLRN) reported quarterly losses of $(1.16) per share. This is a 75.76 percent decrease over losses of $(0.66) per share from the same period last year. The company reported $34.20 million in
Merck Pushes Acceleron Buyout By Refiling For Antitrust Review
Merck & Co Inc (NYSE:MRK) revealed that it had temporarily withdrawn its premerger notification and report form. The company said it…
Bloomberg Reported Late Wednesday Bristol-myers Squibb Plans to Tender Its Shares in Acceleron Pharma Following Merck Agreement to Acquire the Biotech Company
https://www.bloomberg.com/news/articles/2021-10-21/bristol-myers-said-to-plan-acceleron-stake-exit-with-merck-deal
Holocene Advisors Says Believes Merck’s Proposed Offer of $180 Per Share for Acceleron Significantly Undervalues Company
Long-term Holder Does Not Intend to Tender Shares into Merck's Offer
Holocene Advisors, LP ("Holocene"), a fundamental investment management firm and significant shareholder of Acceleron Pharma Inc.
Expert Ratings For Acceleron Pharma
Analysts have provided the following ratings for Acceleron Pharma (NASDAQ:XLRN) within the last quarter:
Jefferies Initiates Coverage On Acceleron Pharma with Hold Rating, Announces Price Target of $180
Jefferies analyst Akash Tewari initiates coverage on Acceleron Pharma (NASDAQ:XLRN) with a Hold rating and announces Price Target of $180.
Where Acceleron Pharma Stands With Analysts
Analysts have provided the following ratings for Acceleron Pharma (NASDAQ:XLRN) within the last quarter:
Raymond James Downgrades Acceleron Pharma to Market Perform
Raymond James analyst Danielle Brill downgrades Acceleron Pharma (NASDAQ:XLRN) from Strong Buy to Market Perform.